Qulipta vs Emgality
A side-by-side look at two neurology medications advertised on TV. Informational only — not medical advice.
Maintained by TVPills Editorial Team · Site updated November 4, 2026 (not a product-label review)
| Attribute | US Qulipta | US Emgality |
|---|---|---|
| Generic name | atogepant Unverified catalogue summary (Generic name) for Qulipta in US; not checked against current local product information. | galcanezumab-gnlm Unverified catalogue summary (Generic name) for Emgality in US; not checked against current local product information. |
| Drug class | See official local label Unverified catalogue summary (Drug class) for Qulipta in US; not checked against current local product information. | See official local label Unverified catalogue summary (Drug class) for Emgality in US; not checked against current local product information. |
| Treats | Migraine prevention Unverified catalogue summary (Treats) for Qulipta in US; not checked against current local product information. | Migraine prevention and episodic cluster headache in adults Unverified catalogue summary (Treats) for Emgality in US; not checked against current local product information. |
| Category | Neurology Unverified catalogue summary (Category) for Qulipta in US; not checked against current local product information. | Neurology Unverified catalogue summary (Category) for Emgality in US; not checked against current local product information. |
| Manufacturer | AbbVie Inc. (manufactured for) Unverified catalogue summary (Manufacturer) for Qulipta in US; not checked against current local product information. | Eli Lilly Unverified catalogue summary (Manufacturer) for Emgality in US; not checked against current local product information. |
| Year approved | — Unverified catalogue summary (Year approved) for Qulipta in US; not checked against current local product information. | — Unverified catalogue summary (Year approved) for Emgality in US; not checked against current local product information. |
| Catalogue warning level | Safety summary withheld — check official label Unverified catalogue summary (Catalogue warning level) for Qulipta in US; not checked against current local product information. | Safety summary withheld — check official label Unverified catalogue summary (Catalogue warning level) for Emgality in US; not checked against current local product information. |
| Est. TV ad spend | $120M | $110M |
| Side effects and serious risks | — Unverified catalogue summary (Side effects and serious risks) for Qulipta in US; not checked against current local product information. | — Unverified catalogue summary (Side effects and serious risks) for Emgality in US; not checked against current local product information. |
Sources and editorial standards
Use the current DailyMed labels to verify approved uses, boxed warnings, and side effects for each medication. Label results can differ by product, strength, and formulation.
Page updated November 4, 2026; the linked resources have not necessarily been reviewed on this date.
Frequently asked questions
Is Qulipta or Emgality better?
This directory does not compare clinical effectiveness or safety. Listing Qulipta and Emgality together does not establish shared approved indications, equivalence or suitability as substitutes. Consult the correct local labels and your prescriber.
What's the difference between Qulipta and Emgality?
The table shows catalogue identification and estimated advertising information for Qulipta and Emgality, not a verified medical comparison. Medical descriptions, mechanisms and safety summaries are withheld.
Which one spends more on TV ads?
Qulipta has the larger estimated TV advertising budget of the two.